Intravenous Versus Combined Oral and Intravenous Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Elective Colorectal Surgery: A Double-blinded Multicenter Prospective Randomized Controlled Trial
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 920
- 试验地点
- 2
- 主要终点
- occurrence of any SSI within 30 days after surgery.
研究概览
简要总结
To assess the effects of a combined antimicrobial prophylaxis using oral ornidazole (the day before surgery) and intravenous cephalosporin (before surgical incision) with that of intravenous cephalosporin alone (standard of care) in combination with oral placebo on the incidence of SSI within 30 days after elective colorectal surgery.
详细描述
Surgical site infection (SSI) is a major cause of nosocomial infection in surgical patients, with the highest rates being reported (ranging from 15% to 30%) in colorectal surgery. SSI is an independent predictor of postoperative mortality and is associated with longer hospital stay, a 5-fold likelihood of postoperative readmission and a 2- to 3-fold increase in costs of care. Given the high prevalence and financial burden associated with SSI, American and European guidelines have been issued providing evidenced-based recommendations for the prevention of postoperative SSI. However, the prevalence of SSI remains high despite adherence to these guidelines and the application of evidence-based preventive measures.
Risk factors for SSI, whether modifiable or not, are mainly related to the patient condition (including age, severe comorbidity, diabetes, nutritional status, steroid use, smoking, and immunosuppression) and/or the surgical procedure (especially the surgical duration and skin disinfection). The prevention of SSI consists of several individual measures, and antibiotic prophylaxis covering aerobic and anaerobic bacteria is highly recommended in patients scheduled to elective colorectal resection, with French and European guidelines recommending the administration of intravenous cephalosporin within 30 minutes before surgical incision.
Recent data from retrospective studies and two meta-analyses of clinical trials provided compelling arguments that oral antibiotic administration before surgery in addition to conventional intravenous prophylaxis may be useful in further reducing by almost 75% the incidence of SSI (relative risk 0.55 [CI95%: 0.41 to 0.74]) after elective colorectal cancer surgery.
However, most of these studies have limitations precluding extrapolation of data into routine care, especially:
- prolonged duration of intravenous antibiotic administration, which is no longer recommended in elective surgery;
- the use of antibiotics for oral prophylaxis whose availability is limited;
- only a few studies focused specifically on colorectal resection;
- most studies did not include enhanced recovery after surgery (ERAS) programs, which was found to improve outcome following colorectal surgery, and
- most studies have used mechanical bowel preparation, which is no longer recommended in colonic surgery while the issue still remains open for rectal surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18
- •Laparoscopic or non-laparoscopic elective colorectal surgery
排除标准
- •Non elective colorectal surgery (emergent surgery and/or reintervention or revision of a previous colorectal procedure)
- •Significant concomitant surgical procedure (e.g., liver resection for metastasis)
- •Bacterial infection at the time of surgery or antimicrobial therapy up to 2 weeks before surgery
- •Inflammatory bowel disease
- •Severe obesity (defined as a BMI >35 kg/m2)
- •Known history of hypersensitivity to β-lactams and imidazoles
- •Preoperative severe impairment in renal function (creatinine clearance (MDRD) < 30 ml/min)
- •Patients with known colonization with multidrug-resistant digestive bacteria, especially multidrug-resistant gram-negative bacteria (requiring specific infection control measures)
- •Allergy to lactose, galactose intolerance, Lapp lactase deficiency or glucose/galactose malabsorption (rare metabolic disease)
- •Pregnant women, breastfeeding women, women of childbearing age without effective contraceptive- Refusal to participate or inability to provide informed consent
研究组 & 干预措施
ornidazole
oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery. Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance
干预措施: ornidazole (Drug)
placebo
oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery. Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance
干预措施: Placebo (Drug)
结局指标
主要结局
occurrence of any SSI within 30 days after surgery.
时间窗: 30 days after surgery
The primary end point of the trial is the occurrence of any SSI within 30 days after surgery. SSI will be classified as superficial, deep and/or organ-space infection according to validated and well-defined criteria developed by the Centers for Disease Control and Prevention (CDC).
次要结局
- Number of postoperative complications(30 days after surgery)
- Number of surgical complications: anastomotic leakage and the need for abdominal reoperation and/or radiological intervention(30 days after surgery)
- Incidence of individual types of SSI according to the group of treatment(30 days after surgery)
- Duration of hospital stay(30 days after surgery)
- All-cause mortality(90 days after surgery)
- Time to introduction of adjuvant chemotherapy related to SSI(30 days after surgery)
- Postoperative syndrome of systemic inflammatory response (Infectious complications)(30 days after surgery)
- Sepsis (Infectious complications)(30 days after surgery)
- Septic shock (Infectious complications)(30 days after surgery)
- Arrhythmia (Cardiovascular complications)(30 days after surgery)
- Myocardial infarction (Cardiovascular complications)(30 days after surgery)
- Acute cardiac failure (Cardiovascular complications)(30 days after surgery)
- Pneumonia (Respiratory complications)(30 days after surgery)
- Need for postoperative reventilation (Respiratory complications)(30 days after surgery)
- Renal dysfunction(30 days after surgery)
- Time to initiation of adjuvant chemotherapy(30 days after surgery)
- Need for hospital readmission(30 days after surgery)
- Unexpected admission to intensive care unit(30 days after surgery)
- Hospital free days(30 days after surgery)
- All-cause mortality(30 days after surgery)
